Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy as treatment of unresected locally advanced head and neck cancer squamous cell cancer (HNSCC): A meta-analysis of randomized trials.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 6012-6012 ◽  
Author(s):  
Wilfried Budach ◽  
Edwin Boelke ◽  
Kai Kammers ◽  
Stephan Gripp ◽  
Christiane Matuschek
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Induction Chemotherapy ◽  
Squamous Cell ◽  
Randomized Trials ◽  
Squamous Cell Cancer ◽  
Meta Analysis ◽  
Cell Cancer ◽  
Locally Advanced ◽  
Advanced Head

Role of induction chemotherapy in downstaging of locally advanced head-and-neck squamous cell cancer

2018 ◽  
Vol 7 (6) ◽  
pp. 221
Author(s):  
Veenita Yogi ◽  
ManishKumar Ahirwar ◽  
OP Singh ◽  
HU Ghori ◽  
Vivek Tiwari ◽  
...  
Keyword(s):  
Head And Neck ◽  
Induction Chemotherapy ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Neck Squamous Cell Cancer

Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4029-4029 ◽  
Author(s):  
M. Suntharalingam ◽  
T. Dipetrillo ◽  
P. Akerman ◽  
H. Wanebo ◽  
B. Daly ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Locally Advanced ◽  
Complete Response ◽  
Grade 3

4029 Background: Cetuximab is an IgG1, chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor. Cetuximab improves survival when combined with radiation for patients with locally advanced head and neck cancer. We evaluated the safety and efficacy of the addition of cetuximab to concurrent chemoradiation for patients with esophageal and gastric cancer. Methods: Patients with adenocarcinoma or squamous cell cancer of the esophagus or stomach without distant organ metastases were eligible. Patients with locally advanced disease from mediastinal, celiac, portal and gastric lymphadenopathy were eligible. Surgical resection was not required. Clinical complete response was defined as no tumor on postreatment endoscopic biopsy. Patients received cetuximab, 400mg/m2 week #1 then 250 mg/m2/week for 5 weeks, paclitaxel, 50 mg/m2/week, and carboplatin, AUC =2 weekly for 6 weeks, with concurrent 50.4 Gy radiation. Results: Thirty-seven patients have been entered. The median age was 61 (range of 30–87). Thirty-four have esophageal cancer and 3 have gastric cancer. Of the patients with esophageal cancer, twenty-five have adenocarcinoma and nine have squamous cell cancer. Thus far, 30 patients have completed treatment and are evaluable for toxicity. There have been no grade 4 non-hematologic toxicities and 1 pt had grade 4 neutropenia (3%). Six patients (20%) had grade 3 esophagitis. Other grade 3 toxicities included dehydration (n=5), rash (n=9), and paclitaxel/cetuximab hypersensitivity reactions (n=2). Eighteen of 27 patients (67%) have had clinical complete response. Seven pts out of 16 (43%) who have gone to surgery have had a pathologic CR. Conclusions: Cetuximab can be safely administered with chemoradiation for patients with esophageal cancer. Consistent with the data in head and neck cancer, cetuximab increases cutaneous toxicity but does not increase mucositis/esophagitis when combined with chemoradiation. Further evaluation is ongoing. [Table: see text]

scholarly journals Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e51526 ◽  
Author(s):  
Hao Qin ◽  
Jie Luo ◽  
Yuan-Ping Zhu ◽  
Hai-Li Xie ◽  
Wei-Qiang Yang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Induction Chemotherapy ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Locally Advanced ◽  
Advanced Head
Sign in / Sign up

Export Citation Format

Share Document